BDC-1001

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerNCT05954143BOLTPhase 2Terminated2024-09-20Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.